F3 Platform Biologics, Inc. (JDRR)

F3 Platform Biologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	-	0.37	1.89
Research & Development	-	0.25	0.03
Operating Expenses	-	0.62	1.93
Operating Income	-0.78	-0.62	-1.93
Interest Expense / Income	0.31	0.3	0.28
Pretax Income	-1.09	-0.93	-2.21
Net Income	-1.09	-0.93	-2.21
Free Cash Flow	-0.45	-0.39	-0.1
EBITDA	-0.78	-0.62	-1.93
EBIT	-0.78	-0.62	-1.93

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).